MOST TRUSTED NEWSWIRE PRESS RELEASE DISTRIBUTION
PRTODAY / NewswireToday press release distribution service network
Written by / Agency / Source: Frost & Sullivan
Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Waters Corporation Earns New Product Innovation Award with First SmartMS-enabled Biopharmaceutical Solution - Corporation has earned Frost & Sullivan’s 2019 New Product Innovation Award by offering the BioAccord LC-MS System, the first SmartMS-enabled biopharmaceutical solution with intelligent software and application-focused chemistries
Waters Corporation Earns New Product Innovation Award with First SmartMS-enabled Biopharmaceutical Solution

 

NewswireToday - /newswire/ - Santa Clara, CA, United States, 2020/05/29 - Corporation has earned Frost & Sullivan’s 2019 New Product Innovation Award by offering the BioAccord LC-MS System, the first SmartMS-enabled biopharmaceutical solution with intelligent software and application-focused chemistries.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

The BioAccord LC-MS System is the first smart MS-enabled solution that makes LC-MS accessible for the analysis of biopharmaceuticals in development and QC. The system is a self-calibrating and self-optimizing tool that helps scientists to make informed decisions at the point of need. The system is the first to incorporate SmartMS that uses an intelligent health check capability to self-diagnose any issues with the instrument’s status and either automatically make a correction or give the user a step-by-step guide for the remedy.

High resolution mass spectrometry is an indispensable tool in the analysis of peptide, protein and nucleic acid therapeutics, where the complexity of the molecules requires more comprehensive data to ensure product quality. There is a recognised knowledge gap in pharmaceutical development and QC that has restricted the adoption of traditional, more complex high resolution mass spectrometers. Scientists have had to rely on central analytical facilities within their companies or outsource to third parties for analytical data, which can lead to delays in the information required to make critical decisions. In the development of BioAccord, Waters Corporation have addressed these obstacles in several ways. The self-optimisation and healthcheck capabilities reduce the burden on the user and ensure that the system is always producing high quality data; the system is set up in the users laboratory using installation tests that are relevant to the user’s applications so that the system is optimized for the intended use; Waters applications chemists follow up the installation with application-specific training on peptide mapping, intact mass analysis or glycan analysis using Waters developed methods and pre-packaged application kits. Time to market is a critical factor in the development of therapeutics; being able to deploy the BioAccord LC-MS system at the point of need allows informed decisions to be made more quickly thus accelerating the development process.

The BioAccord system is controlled by waters_connect, a scientific information system that enables streamlined workflows and end-to-end compliance from sample to result. With this system, customers no longer have to rely on separate software for data acquisition and processing. By having all parts of the process in one package, the software itself tracks and leads the workflow process. Software also comes with pre-defined, compliance-ready workflows so customers can run the programs right away. The pre-defined workflows include intact mass analysis of proteins and oligonucleotides, monoclonal antibody (mAb) subunit analysis, released n-glycan analysis and peptide mapping/multi-attribute monitoring (MAM). The waters_connect software merges high performance LC and MS into a single system that incorporates data acquisition, processing, visualization, reporting and configurable compliance tools. It can be used as a workstation installation or within a networked laboratory environment.

Waters Corporation was founded in 1958, and in 2018 it hit $2.4 billion in revenues. The company’s incredible customer service success hinges to its 7,200 employees, 54% of which are associated with sales and service roles, maintaining direct links with its global customer base. The company operates in 35 countries, including 15 manufacturing facilities, which speaks volumes about the superior service customers can access. Waters Corporation dedicates significant attention to customer service, which results in abundant brand loyalty. During the product development process Waters’ product and market-focused teams actively elicit feedback, giving considerable attention to customer sentiment, in the design of new products.

The BioAccord LC-MS system was designed with productivity in mind, positioning the user to acquire and process data with a purpose-built LC-MS platform. Frost & Sullivan recognizes how this solution identifies and resolves issues more quickly and thereby improves system productivity. High-performance separations performed by Waters Corporation’s UPLC technology are well-known across the industry. The system is integrated with ACQUITY UPLC I-Class PLUS System and UNIFI software to offer an attractive solution to customers. ACQUITY UPLC I Class PLUS System maximizes the sensitivity and resolution of customers’ methods, while enhancing both data quality and productivity. The core of the system is the ACQUITY RDa mass detector which is designed with a small footprint for space-restricted laboratories but produces very high-quality accurate MS data. The system is paired with application-specific chemistries and standards, allowing scientists to achieve new levels of resolution and consistency in chromatographic separations.

Waters Corporation has developed the industry’s first-ever truly “smart” mass spectrometer that will allow non-mass spectrometrist customers to perform analysis independently with the capability of BioAccord LC-MS system. The system provides high levels of usability, reliability, sensitivity, and deteccompliance. The company’s solutions have an incredibly positive impact on customers who laud the industry-leading separations achievable by ultra-high performance liquid chromatography. For the strong overall performance of the BioAccord LC-MS system, Waters Corporation has earned the 2019 Frost & Sullivan New Product Innovation Award.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Frost & Sullivan

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick NewswireToday Visibility Checker

 

Distribution / Indexing: [+]  / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma / BioTech / Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Waters Corporation Earns New Product Innovation Award with First SmartMS-enabled Biopharmaceutical Solution

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name NewswireToday and LINK as the source.
 
Publisher Contact: Janani Balasundar - Frost.com 
janani.balasundar[.]frost.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Frost & Sullivan securities in any jurisdiction including any other companies listed or named in this release.

Pharma / BioTech / Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Frost & Sullivan / Company Profile


Read Pharma / BioTech / Nutrition Most Recent Related Newswires:

Technological Advancements in Manufacturing Boost the Cell and Gene Therapy Market Says Frost & Sullivan
Huami Corp and Royal DSM Announce Collaboration on Wearable Technologies and Health Tracking for Personalized Nutrition
DSM Expands Animal Nutrition & Health Operations in China with Opening of Seventh Premix Plant
Biosurfactants and Natural Preservatives Drive Innovation for Functional Ingredients in Personal Care Market Finds Frost & Sullivan
Ypsomed Collaborates with SCHOTT and Lonza to Develop A Comprehensive Solution for Combination Products Based on Patch Injectors
DSM Unveils Purpose-led Brand Strategy Marking Transition to End-to-end Partner in Nutrition and Health
Ipsen to Present 12 Abstracts At the 11th World Congress for Neurorehabilitation (WCNR) Virtual Congress
Imec Announces elPrep5 - the Newest Version of its Software Platform for DNA Analysis
Ipsen Showcases Commitment to Patient-centric Advances in Oncology with Record Number of Abstracts to be Presented At ESMO 2020 Virtual Congress
Global Phase 3 Clinical Study of Pridopidine in Huntington’s Disease Announced
Ipsen to Present New Insights At ASBMR for Potential Treatment of Ultra-rare Disease Fibrodysplasia Ossificans Progressiva (FOP)
Ipsen to Present Results from MOVE, the First Global Phase III Trial in Fibrodysplasia Ossificans Progressiva (FOP) At ASBMR 2020 Annual Meeting
DSM Ignites New Strategic Initiative to Transform Global Animal Nutrition and Health
Jamjoom Pharmaceuticals Earns Acclaim from Frost & Sullivan for its Dominance in the KSA Pharma Market
DSM and Avril Complete Creation of Joint Venture to Develop Plant-based Protein

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  JobsWare.com

Visit  Limelon Advertising, Co.





 
  ©2020 NewswireToday — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com newswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)